secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001193125-23-232477
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma shareholders approve 2017 Plan amendment, elect directors, ratify auditor
--------------------------------------------------------------------------------

- Elected eight directors including Arie Belldegrun, Elizabeth Barrett, Cynthia M. Butitta, and Fred E. Cohen.
- Approved amendment to 2017 Equity Incentive Plan increasing authorized shares by 450,000.
- Approved grant of Performance Stock Units to CEO under the amended plan (13,115,279 for, 3,363,390 against).
- Advisory say-on-pay passed with 13,668,197 for, 3,118,618 against, 35,305 abstentions.
- Ratified PricewaterhouseCoopers LLP as independent auditor for next fiscal year (22,507,002 for, 16,731 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/0001193125-23-232477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523232477/d485257d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-232477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer